Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024. Additionally, the Company is in advanced stages of development and testing of 9 other skincare products anticipated to launch over Spring and Summer 2024.

The Carmell skincare product portfolio:

1. Carmell G.L.E.E. – limited edition exclusive product by invitation only. Launching in March 2024.
2. Youth Restoring formula – daily cream to reduce the appearance of wrinkles and blemishes.
3. Treatment Enhancing formula – for use by professional care providers to soothe and repair the skin barrier following aesthetic treatments.
4. Rapid Recovery formula – for use by professional care providers to accelerate recovery.
5. Undereye AM formula – reduce the appearance of dark circles and crepey skin as well as photoprotection during the daytime.
6. Undereye PM formula – calm and strengthen undereye skin at bedtime.
7. Ultra-Brightening formula – extra strength anti-blemish and skin brightening action.
8. Ultra-Hydrating formula – extra strength skin hydrating and plumping action.
9. Ultra-Gentle formula – formulated for daily use for the most sensitive skin types.
10. MotherCare formula – formulated for sensitive and mechanically stressed skin during pregnancy.

Carmell’s suite of skincare products are based on the Carmell Secretome^TM, a potent cocktail of 1000+ growth factors and proteins extracted from allogeneic human platelets sourced from US FDA-approved tissue banks. The technology underpinning the Carmell Secretome has been extensively tested for safety and efficacy, significantly surpassing standards set by the Cosmetics Industry, including robust results from a prospective, randomized, multi-center Phase 2 human trial.

Besides the Carmell Secretome^TM, the Company has developed a novel micellar nanoparticle formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen^TM, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell’s micellar formulations do not utilize mineral or vegetable oils across their entire product line and are designed to be non-comedogenic.

In addition to the aforementioned skincare products, Carmell is also developing a Men’s Skincare Line and a topical Haircare line of products. Carmell benefits from the ongoing guidance around product development and testing from a Scientific Advisory Board comprised of a dozen Key Opinion Leaders associated with the best technology advancements in the Aesthetics Industry.

Carmell products are manufactured in-house at their Pittsburgh facility in compliance with current Good Manufacturing Practice (cGMP) guidelines. Reflecting their commitment to quality, Carmell has developed and implemented a robust panel of tests covering everything from raw materials to in-process testing to final product testing as tracked and documented by their fully electronic Quality Management System. Carmell’s manufacturing processes surpass several guidelines in the proposed Modernization of Cosmetic Regulations Act (U.S. Food and Drug Administration) anticipated to be effective July 1, 2024. In preparation for at-scale commercial operations, Carmell has set up a fully functional online store integrated with Oracle NetSuite on the backend and logistics partners on the frontend.

About Carmell
Carmell is a bio-aesthetics company that utilizes the human platelet secretome to topically deliver more than a thousand proteins and growth factors to support skin and hair health. Carmell’s quality ethos is based on rational cosmetics design coupled with a focus on clean formulas that omit the Foul Fourteen, 14 commonly used chemicals that may cause harm to our health. The Company is focused on developing topical cosmetics tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. For more information, visit www.carmellcosmetics.com

Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the attributes and benefits of Carmell’s products including R&D products under development. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the ability to recognize anticipated benefits from their commercial products, R&D pipeline, distribution agreements, changes in applicable laws or regulations, the possibility that Carmell may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those to be included under the header “Risk Factors” in the 10-Q statement on filed by Carmell with the SEC on November 15, 2023, as amended. Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact
Bryan Cassaday
Chief Financial Officer
bc@carmellcorp.com